AviadoBio.

AviadoBio develops gene therapies for neurological conditions, leveraging its understanding of the brain and proprietary delivery technologies. The company aims to overcome challenges in delivering gene therapies to the brain, potentially halting or reversing neurodegenerative diseases. Its innovative approach is based on pioneering research from King's College London and the UK Dementia Research Institute.

Funding Round: Equity

Funding Amount: $20M

Date: 08-Oct-2024

Investors: Astellas Pharma Inc., New Enterprise Associates (NEA), Monograph Capital, F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), SV Health Investor’s Dementia Discovery Fund (DDF), Advent Life Sciences, EQT Life Sciences (Dementia Fund), LifeArc Ventures

Markets: Biotechnology, Gene Therapy, Neuroscience, Healthtech

HQ: London, England, United Kingdom

Founded: 2019

Website: https://www.aviadobio.com/

LinkedIn: https://www.linkedin.com/company/aviadobio/

Twitter: https://twitter.com/aviadobio?lang=en

Instagram:

Facebook: https://www.facebook.com/AviadoBio

Crunchbase: https://www.crunchbase.com/organization/aviadobio

Pitchbook: https://pitchbook.com/profiles/company/442831-33